Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities

HDFC Securities has come out with its fourth quarter (Jan-March’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Alkem Labs to report net profit at Rs. 130 crore down 1.5% year-on-year (down 21.4% quarter-on-quarter).

Net Sales are expected to increase by 12.7 percent Y-o-Y (down 19 percent Q-o-Q) to Rs. 1,410 crore, according to HDFC Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 5.9 percent Y-o-Y (down 56 percent Q-o-Q) to Rs. 160 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.